News
Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback